Novo Nordisk A/S ADR (NVO) faced challenges in 2025, including trimmed growth forecasts, pricing pressure, and competition from Eli Lilly. However, the company’s FDA approval for a GLP-1 weight loss pill, “Wegovy-in-a-pill,” marked a strategic comeback, shifting the narrative. Novo’s Q3 earnings showed resilience with total revenue up 5% YoY, driven by strong demand for diabetes and obesity treatments. Analysts hold a “Moderate Buy” consensus rating on Novo Nordisk stock, with a Street-high target of $70, suggesting potential for a 33% increase. Despite challenges, Novo remains a key player in the healthcare sector, focusing on chronic diseases and innovative treatments.

Read more at Barchart: As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?